Resources

Company secures additional financing to advance clinical programmes in Immuno-Oncology and Inflammatory bowel disease through to data readout

Mestag was awarded a “Transforming Cancer Therapeutics” grant of £1.5/$1.9 million from Innovate UK to accelerate MST-0300, which is designed to induce tertiary lymphoid structures (TLS) in solid tumors, as an exciting and novel therapeutic approach.

Collaborative Project to Develop Next-Generation Cell Platform for Viral Vector Production Receives £1.1 Million Grant from Innovate UK & NRC

FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, today hosted a celebration for the opening of its microbial fermentation manufacturing facility in Billingham.

Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed Carlos Garcia-Echeverria, Katharina Kreymborg and Karen Lackey as the first members of its Therapeutic Innovation board to steer its drug discovery strategy.

Moa Technology has announced excellent results in multi-country field trials of promising new classes of herbicide with novel modes of action recently discovered by the company. Weeds pose a serious and increasing threat to food security around the world. With over 270 species of weeds now resistant to existing commercial herbicides, and no new broad-spectrum herbicides brought to market in the last forty years, farmers globally are running out of tools to protect their harvests. Spun out of Oxford University in 2017, Moa has developed proprietary technology to discover a whole new generation of synthetic and bio-herbicidal compounds based on novel modes of action, to provide farmers with safe, cost-effective, technologically-advanced solutions at a pace weeds cannot match. In the last three years, Moa’s platform has already screened over 750,000 compounds and discovered over 70 promising novel modes of action areas. In July 2024, Moa signed a major partnership with Nufarm to co-develop and commercialise one of these new chemical series.

eXmoor’s Cell & Gene Therapy Centre can now offer a full range of GMP services for cell and gene therapies including manufacture, fill/finish, packaging, labelling, and shipping to global clinical sites

London BioScience Innovation Centre (LBIC) is delighted to announce that it has entered into an Agreement for Lease with Baseimmune Ltd.

Vertex Pharmaceuticals announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassaemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel), from today.

Scotland's largest vaccine producer, Valneva Scotland Ltd, based in Livingston, has achieved an esteemed Silver Award for health and safety from the Royal Society for the Prevention of Accidents.

Novo Holdings will invest £50m in Oxford Nanopore as part of an equity issue and intends to add to this investment over time, with further purchases in the secondary market, subject to availability and price (among other factors).

Press Release: Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes.

Medannex will work in close collaboration with senior scientists at ARU (Cambridge) and world-leading paediatric oncologists to deliver this important project. MDX-124 is the first clinic-ready agent to target annexin-A1, a protein known to drive numerous cancers and other diseases. In preclinical tests, MDX-124 has been shown to stop the growth and spread of certain cancers, as well as harnessing the immune system to attack tumours. MDX-124 is currently being evaluated in a first-in-human Phase 1b oncology study in adults (‘ATTAINMENT’). Recent data mining of a paediatric genomics database and staining of tumour tissue revealed that annexin-A1 is highly expressed in osteosarcoma, making MDX-124 a strong candidate to treat this disease.

The studies presented this week at the Society of Neurointerventional Surgery (SNIS) underline the company’s rigorous evidence-based approach to developing and validating novel AI solutions that can help to optimize patient care across stroke networks.